ContractExhibit A • April 1st, 2016 • Vivo Ventures VI, LLC • Biological products, (no disgnostic substances)
The undersigned hereby agree that the statement on Schedule 13D to which this Agreement is annexed as Exhibit 1, and any amendments thereto, is and will be filed on behalf of each of them in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended.
JOINT FILING AGREEMENTJoint Filing Agreement • September 12th, 2018 • Vivo Ventures VI, LLC • Pharmaceutical preparations
In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the entities listed below agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock, $0.001 par value, of KalVista Pharmaceuticals, Inc., and further agree that this Joint Filing Agreement be included as an Exhibit to such joint filing.
Agreement of Joint FilingJoint Filing Agreement • May 5th, 2017 • Vivo Ventures VI, LLC • Pharmaceutical preparations
The undersigned hereby agree that a single Schedule 13G (or any amendment thereto) relating to the Ordinary Shares/American Depositary Shares of Verona Pharma plc shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Schedule 13G.
